L3VLUP
ProSign in

CLDX · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CLDXVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CLDX
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterCLDXVRTX
Q3 20201 holders, $2.5m31 holders, $21.9bn
Q4 20203 holders, $7.7m30 holders, $18.4bn
Q1 20212 holders, $5.5m31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 20211 holders, $41m35 holders, $10.1bn
Q4 20213 holders, $40m28 holders, $12.4bn
Q1 20223 holders, $83m23 holders, $16.1bn
Q2 20223 holders, $65m25 holders, $18.1bn
Q3 20222 holders, $5.7m22 holders, $18.4bn
Q4 20225 holders, $265m28 holders, $18.4bn
Q1 20232 holders, $152m26 holders, $21.4bn
Q2 20233 holders, $216m27 holders, $24.7bn
Q3 20233 holders, $189m33 holders, $24.3bn
Q4 20234 holders, $432m32 holders, $28.6bn
Q1 20244 holders, $444m31 holders, $29.8bn
Q2 20244 holders, $450m29 holders, $33.4bn
Q3 20243 holders, $447m27 holders, $33.5bn
Q4 20243 holders, $341m26 holders, $28.5bn
Q1 20253 holders, $221m21 holders, $35.4bn
Q2 20253 holders, $90m21 holders, $32.3bn
Q3 20253 holders, $253m22 holders, $25.9bn
Q4 20254 holders, $283m26 holders, $31.8bn
Q1 20264 holders, $393m25 holders, $31.8bn
Q2 20263 holders, $384m26 holders, $34.6bn
CLDX

Celldex Therapeutics Inc New

Holders
3
Reported value
$341m
Buyers
1
Sellers
2

Breadth -1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$28.5bn
Buyers
14
Sellers
13

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CLDX (1)

Point72 Asset Management LP

Only VRTX (24)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →